Currently Viewing:
Supplements The Great Debate Part II: Should Managed Care Rely on Cost Sharing to Manage Big-ticket Biologics?
The Debate
The Great Debate Part II
Diana I. Brixner, RPh, PhD; Leslie Fish, RPh, PharmD; and Wayne M. Lednar, MD, PhD
The Case for Cost Sharing for Biologic Therapies
Leslie Fish, RPh, Pharm D
The Case Against Excessive Cost Sharing
Diana I. Brixner, RPh, PhD
Balancing Quality Employee Benefits With Cost Sharing
Wayne M. Lednar, MD, PhD
Currently Reading
The Great Debate Part II: Should Managed Care Rely on Cost Sharing to Manage Big-ticket Biologics?
Mark Zitter, MBA
Participating Faculty

The Great Debate Part II: Should Managed Care Rely on Cost Sharing to Manage Big-ticket Biologics?

Mark Zitter, MBA

The past several years have seen a rapid introduction of biologic therapies with dramatic efficacy profiles and equally impressive price tags. Approximately 130 biotechnology drugs and vaccines have been approved by the US Food and Drug Administration, of which more than 70% have been approved within the past 6 years.1 In addition, hundreds of new products are in various phases of clinical trials. This trend has raised complex pharmacoeconomic questions for providers, payers, and patients and has presented society with difficult ethical questions.

As costs for biologics skyrocket and injectable benefits are carved out, managed care organizations (MCOs) are experimenting with radical new cost-sharing approaches for biotechnology therapies. Whereas copayments for typical medications sit in the $15 to $50 range, cost sharing for expensive biologics could exceed $1000 for a single dose. What are the implications for utilization, patient choice, outcomes, and costs? Will payers face increased legal liability, public relations damage, and member defections? What ethical issues are involved? Can copayment and coinsurance policies differentially encourage appropriate versus inappropriate use? And how can health plans hope to manage biologics utilization without increased cost sharing?

During a moderated debate session held during the Academy of Managed Care Pharmacy (AMCP) annual meeting in August 2004, Sean Sullivan, PhD, RPh, of the University of Washington, suggested the use of consensus panels for establishing treatment guidelines for specialty pharmaceuticals, because they are useful mechanisms for developing credible recommendations that incorporate new and narrowly tested technologies. Of particular interest within this second phase of the great debate was Dr Sullivan's observation that a thoughtful approach to consensus guidelines for specialty pharmaceuticals can promote a best practice approach that will lead to the cost-effective use of medical resources.

It is important to note how managed care has responded to the use of guidelines for specialty pharmaceuticals. The implementation of specialty pharmacy networks and patient self-administration of injectables has been used to reduce office visit costs, limit physician billing, and improve patient adherence. Two other MCO responses involve benefit design and copayment structures. As discussed later in this supplement, payers are increasingly shifting injectable and biologic products from the medical or mixed benefit category into the pharmacy benefit category, or at least managing these therapies through traditional pharmacy techniques.

Another technique used to control specialty agents is the set of "use rules" adopted by each MCO for every agent. These rules deal with prior approval from physicians or specialists, how closely the approved uses and dosing match the product labeling, and whether past failure with another class or agent is required. These rules, of course, comprise the utility and practicality of treatment guidelines, the subject of the first debate.

Although 65% of AMCP attendees who participated in the first debate reported that they want more guidelines and less physician preference,2 the gap between evidence-driven medicine and the reality of current guideline usage is wide. In addition to such challenges as insufficient evidence, credibility issues, out-of-date guidelines, and implementation variations, the fact remains that payment criteria for specific treatments vary. Of equal importance is the linkage between treatment guidelines and reimbursement decision making, as seen in 3 of the 5 statements in the Table.



Although many of the medical breakthroughs over the next decade will involve specialty pharmaceuticals, the greatest challenge posed by their use will lie in balancing the medical needs of patients with the economic needs of employers and healthcare administrators. As pointed out by the members on this panel, there is confusion over whether the healthcare system's real motivation is to reduce costs, limit dangerous therapy, or improve care. This supplement to The American Journal of Managed Care aims to provide a greater understanding of this ongoing dilemma and, in particular, its cost considerations.

Impact, Limitations, and Consequences of Increased Cost Sharing

Overview of Healthcare Costs/Pharmaceutical Spending in the United States. According to data released by the Centers for Medicare & Medicaid Services, per capita health spending increased from $5879 in 2003 to $6280 in 2004, accounting for 16% of the gross domestic product (GDP), outpacing growth in the overall economy by 4 percentage points.3 Growth in total publicly funded spending slowed (from 8.2% in 2003 to 7.9% in 2004), as did private sector spending (7.6% in 2004 compared with 8.6% in 2003), whereas out-of-pocket spending grew by 5.5%.3

In terms of healthcare expenditure projections, national health costs are expected to reach $3.6 trillion in 2014, growing at an average rate of 7.1% annually from 2003 to 2014. Healthcare spending is projected to reach 18.7% of the GDP by 2014, an increase from 15.3% in 2003.4 Assuming no changes in the delivery and payment of healthcare, national healthcare expenditures can be expected to outpace GDP by the year 2060 (Figure 1), a clear impossibility. This raises the question, how do we control healthcare costs and still provide high-quality healthcare?3



Cost Versus Quality of Care Concerns. In a supplement to Disease Management entitled "The Health of American Healthcare," and sponsored by McKesson Corporation in 2004, Gary Owens, MD, vice president of medical management and policy at Independence Blue Cross (IBC), stated, "Biotechnology innovations are changing the way injectables are used. Instead of being used intermittently for treating short-term, acute illnesses in the office, the new biological injectables are intended for use in treating long-term, chronic illnesses. By 2005, IBC projects that spending for injectables will increase by one third."4 Based on Dr Owens' statement, as well as the overall rapid growth of this segment of the industry, it is clear that specialty pharmaceuticals are becoming more ubiquitous. According to a survey by Pharmaceutical Research and Manufacturers of America, nearly 150 different diseases are being targeted by these products, including 154 for cancer, 43 for infectious disease, 26 for autoimmune disorders, 16 for neurological disorders, and 17 for human immunodeficiency virus/acquired immunodeficiency syndrome. It is apparent that specialty treatments will soon be available for almost every chronic disease.5

In the minds of all healthcare stakeholders–health plan and employer-based administrators, manufacturers, providers, and, in particular, patients–the eventual cost of these therapies are inextricably tied to the quality of care that is offered by them. Confirmation of this belief is found in the eighth annual 2005 health confidence survey cosponsored by the Employee Benefit Research Institute, Matthew Greenwald and Associates, Inc, and grants from 13 private organizations. Findings from this random sample of more than 1000 Americans older than 21 years of age confirm that Americans tend to view cost as one of the least important factors when considering healthcare quality. Simultaneously, however, many Americans believe that cost increases have affected both the way they use healthcare and their financial well-being. Perhaps most telling is that a majority (65%) feel that increased access to information about the effectiveness of treatment options and the quality of healthcare providers (59%) would improve the quality of the healthcare they receive.6

Further data from this study confirm that, despite the increases in cost sharing that employers are asking of their workforces, most Americans appear to value employment- based health coverage above the actual dollar amount that employers pay toward the care. To understand the intricate nature of these findings, an examination of the actions of healthcare stakeholders is needed.

Understanding the Beliefs of Healthcare Stakeholders From the Cost-sharing Perspective

Rising healthcare costs incurred by both patients and payers have captured national attention. The 2004 Annual Employer Health Benefits Survey, compiled by the Kaiser Family Foundation and Health Research and Educational Trust and based on responses from 3017 employers, found that, in spite of escalating premiums, the percentage of premiums paid by covered workers has remained stable over the past few years, at 16% for single coverage and 28% for family coverage. However, employers have increasingly turned to cost sharing to mitigate cost increases. More than half (52%) of executives at large firms (defined as =200 employees) said they were very likely to increase the amount employees pay for health coverage. Of particular interest regarding specific areas of coverage is that the largest percentage of executives said they were likely to increase the amount employees pay for prescription drugs; 18% said they were very likely to do so, and 37% were somewhat likely.7 In a report of this same study, other findings were more alarming. In 2005, the average worker's share of premiums for family health coverage was $2713, and the average employee contribution has increased by more than $1000 in 3 years.8

In our quick poll during this AMCP session (Figure 2), we realized just how stark the lines of this debate are drawn. On one hand, healthcare costs are skyrocketing, and the cost of biologic therapies represent a small but especially fast-growing component of them. At some level, it seems fair that patients should contribute to the cost of their treatment, and it seems logical that such cost sharing may reduce unnecessary treatment. Payers argue that the current third-party payer system has blinded the average consumer to the true cost of the therapy and that patients cannot remain truly engaged in their healthcare without cost transparency.



Conversely, there is strong evidence, at least from the primary care perspective, that any degree of copayment suppresses demand not only for inappropriate care but also for necessary therapy, with the resultant and potentially negative impact on health outcomes. In many cases, studies have shown that increasing patient cost sharing for necessary medications can actually increase overall healthcare costs by suppressing demand for needed medications. The impact is especially strong in conditions such as diabetes, which often have complicated, expensive comorbidities. However, it is too early to tell what impact increasing copayments may have on biologic therapies, because most are too new for any clear long-term data.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up